In short
Podcast Notes: CNBC's "Fast Money" - Episode Summary (5/28/24)
Episode Overview Title: The Next Shoe To Drop In Office Space… And Insmed Surges On Drug Results Description: This episode discusses the challenges in the office real estate market, potential government involvement, and highlights Insmed's remarkable success following positive drug trial results.
Key Segments
- Market Highlights
- NVIDIA Surge:
- Stock increased by nearly 20% in one week and 130% year-to-date.
- Discussion on sustainability of this growth amidst market dynamics.
- Commercial Real Estate Concerns:
- Report indicates worsening conditions in the office market.
- Significant rise in loan modifications (from $117 million to $1.42 billion YoY).
- Analysts express concern that modifications are merely postponing inevitable risks.
- Analysis of Commercial Real Estate (CRE)
- Loan Modifications:
- Increased due to pressures in the office market.
- Modifications primarily affecting B-grade office buildings, especially in suburban areas.
- Interest Rates:
- Current commercial rates are above 7%, significantly higher than the 3-4% rates at which many loans were originally made.
- Concerns about future occupancy and economic stability.
- Regional Bank Vulnerabilities:
- Potential losses anticipated in major markets like London and New York.
- Discussion of how CRE stress may affect the broader economy.
- Insmed's Drug Trial Success
- Brensocadib Findings:
- Positive phase three study results for treating bronchiectasis.
- CEO Will Lewis explains the significance of DPP-1 inhibition and its potential to treat other inflammatory diseases.
- Market Potential:
- Analysts compare Brensocadib to successful drugs like Dupixent and Humira, suggesting significant financial upside.
- The company prepares for regulatory approval and expansion.
- Additional Market Updates
- Kava's Earnings Report:
- Despite a strong earnings beat, Kava shares fell due to prior stock performance.
- Airline Industry Insights:
- United Airlines reaffirms guidance amidst American Airlines' profit warning, impacting stock performance.
- Leasing Resurgence:
- Increased dealership traffic and leasing options as the supply chain normalizes post-chip crisis.
Key Takeaways
- Commercial Real Estate Risk:
- The growing distress in the office segment suggests a potential crisis, with implications for regional banks and the broader economy.
- Pharmaceutical Market Dynamics:
- Insmed's success highlights the potential for biotech firms to significantly impact healthcare with innovative treatments.
- Market Sentiment:
- The episode underscores how market movements can be influenced by macroeconomic factors, interest rates, and investor sentiment.
Conclusion The episode provides a critical look at the intersection of commercial real estate challenges and pharmaceutical advancements, emphasizing the need for investors to stay informed about emerging trends and shifts in market dynamics.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Transcript
Automatic transcript. May contain errors.0:02Live from the NASDAQ market site in the heart of New York City's Times Square. This is Fast Money. Here's what's on tap tonight. Breaking record. Shares of NVIDIA keep defying gravity and maybe even logic. The stock now up nearly 20 percent in just the last week, 32 percent this month, 130 percent since the start of the year. How long can this run continue? We'll debate that. Plus, commercial crunch, a new report painting a bleak picture about the beaten up office space area of the real estate market. We'll go inside the numbers coming up. And later, biotech boom, the details on why shares of InSmed more than doubled today.
0:33The CEO will join us on set. And shares of Kava falling after hours despite posting a big earnings feed. Investors have been gobbling up the stock all year. We'll find out if they're just full right now. I'm Melissa Lee coming to you live from Studio B at the Nasdaq on the desk tonight. Tim Seymour, Courtney Garcia, Dan Nathan and Guy Adami. Well, the Nasdaq closing today above 17 ,000 for the first time, ending the day near session highs. NVIDIA playing a leading role in the Nasdaq's milestone. The chipmaker up another 7 % today, now up 20 % in just the last week. We'll have much more in NVIDIA's record-breaking run in markets in just a minute.
1:06But we begin with the growing fear factor in commercial real estate. A new report suggesting the trouble in the office space market is getting worse. CNBC's Diana Olick has the exclusive details. Diana. Well, Melissa, as pain in commercial real estate drags on most acutely in the office space and the prospect for significantly lower interest rates is pushed further out, we are now seeing a big uptick in loan modifications. In the first quarter of this year, there were$1.42 billion in office loan modifications. That's a huge jump from the just $117 million in the same quarter last year. And all of this is according to new numbers from TREP.
1:43Analysts there say that is not a good sign for the market. It may put a band-aid on the current environment that we're in, but it really just transfers the risk down to future years where borrowers are hoping interest rates are lower, they're hoping occupancies are stronger. But the reality is in 12, 18, 24 months, which the typical extension has been, I don't see a lot of changes happening. Borrowers have to pay a lot for these modifications and the terms are short. Now, the incentive was lower interest rates, but that's now not happening as quickly as most thought. So looking forward, there's much less incentive for additional modifications.
2:21TREP expects office loan mods to increase through this year as there's about $30 billion worth of maturing CMBS office loans left in 2024. Melissa? That's a staggering number, Diana. So I guess the hope is just that rates will be lower, the economy will still be firm in 18 to 24 months. Where are these modifications being concentrated? Where is the most distress right now? Well, you're seeing it in loans that are held in what we call the B office, not the class A office space. The new buildings, they still have really good occupancy. That is in cities like New York City, Washington, D.C., Boston, that is the high end of the office market, is doing fine.
2:57It's those B buildings in suburban markets or in smaller cities that are seeing the most distress. And those are sort of at the midsize to small banks that we see that. But again, this kind of extend and pretend on the modifications, the thought was, yes, like you said, that they would get it to a point where we'd have lower interest rates and everything would work out. But even if you have that equation going down two, three years and the Fed is lowering much more slowly than thought, they have a long way to go to get back to where these loans were originally made in the 3 or 4 percent range from where we are now.
3:28Where are we now, Diana, just for reference, approximately? Well, I mean, commercial real estate is not the same as residential real estate. We're in the 7 percent range. Commercial, it depends on the building and the bond. But we're higher. Yes, in seven, higher than seven. Diana, thanks. Diana Oleks. Sure. I like that extend and pretend because that really captures what is going on in this market. In this pocket of the market, they're hoping, hoping that rates will come down by the time that loan comes due. Well, and that's been part of the dynamic here with Hire for Longer, which is that we really just haven't seen any test on commercial real estate.
4:06Guy's friend, Neil Kashkari, was out there today saying he was also concerned about, he said a lot of things today. One of them was also, he was concerned about commercial real estate. And I think when we look at where we were a year ago when we were just getting through Silicon Valley Bank, CRE and the impact on regional banks was such a big part of that story. The fact is that rates are now as high a year later. They don't seem, if you look at futures, we're not going to have a ton of relief. So extending, as Diana pointed out in terms of a very short-term loan and a relative basis to where they were, a lot of these loans were already come and due.
4:39Okay, so you get kicked out 18 months. As we just said, not a whole lot changes. Kashkari, guy's friend, said specifically about commercial real estate, that he expected losses, big losses to come in markets like London and New York. And in an interview on CNBC, he said that he wouldn't rule out a rate hike. It's a high bar, but he wouldn't take that option off the table at this point. Yeah, listen, I sort of agree, but I mean, this is something that's been way behind the curve in terms of when they wanted to start raising rates and now in terms of when we're theoretically starting to lower rates.
5:08Good for him. I'm sure he's a fan of the show. With all that said, it does come down to interest rates. And again, you know, you saw that five-year auction today, Not particularly good. Ten years rallying. Again, yields are going higher, I should say. Again, I don't think that augurs particularly well. Then you look at sort of the KRE, which has bounced, but not nearly as much as some of these larger money center banks. I think that might be vulnerable. And the one that really sticks out to me, look at Simon Property if we go back eight or nine years. We're basically in an eight-year downtrend from 2016.
5:36It's had a monumental bounce off the bottom. But, again, things haven't gotten that much better. Things have just gotten quiet. But nothing's been fixed, in my opinion. You know, it's interesting, Guy, you just mentioned the KRE, so the regional banking index. You know, we've seen yields go from, what, 435 to 455 just in the last week or so. The KRE is down 6.5%. So I think everything that we've just discussed, everything we heard from Diana, it really shows where the stress might be as things get worse. And I know we've been focused on this since, really, SVB and the regional banking crisis that we had in early 2023.
6:07But it's also important to note the BKX has come off a little bit here, about 4%, while we've seen rates increase again. And so one of the reasons why we keep tracking a lot of this economic data, if the inflationary data kind of firms up, maybe, guys, boy, Kashkari might be right. We might start to see rate hike chances increase a little bit. So that's kind of I think it's worth paying attention to Neil Kashkari guy. Yeah, I think it's too early to say that there's going to be hikes here. But I think when you're looking at the commercial real estate sector, there's really two ways to play this.
6:40So you can look at your regional banks, and that's likely where a lot of the stress is going to be because they're holding the loans for those. When it comes to the real estate side, I think what you're seeing is a lot of people are nervous about REITs and real estate in general. And I think office REIT is specifically the sector that is going to have the issues. There's plenty of other areas in real estate. You look at your industrials, things like cell towers, things like multifamily, or even seeing a lot of that private equity money is going in to buy additional REITs right now. So I think that's something you need to realize is not all REITs are created equal.
7:08And actually commercial and specifically office exposure is pretty small when you're looking at something like the Vanguard Real Estate Index. It's a very small exposure there. And I think that's just something that's important to keep in mind as an investor. It was a very difficult day for treasurers, too. We had a terrible auction. We had a terrible auction after a poor auction yesterday in two years. So we had 70 billion in five years. We've got a big chunk of sevens. You've got the Treasury out later in the week. Actually, I think it's tomorrow they're going to be buying back a lot of weird, funky, off-the-run securities that are hard to bid.
7:37And I just think the pressure on the Treasury market is another part of the story. JGB yields, which I continue to think are going to be a magnet higher as they go higher now that the Bank of Japan is also suddenly in the market saying, we'll just let markets decide. This is what markets do. This is a Bank of Japan that's manipulated the long end of the curve in their bond market forever. So I think this is all pressure on commercial real estate. Yields are going higher. The economy is doing just fine. And that's something that if you think about the U.S. government is a credit worthy buyer and where tax receipts have been coming in less than expected.
8:12It's kind of hard to believe with the job market where it is that tax receipts have been. All these are just small ingredients into a story that says with elections coming and deficits not going to get better with either administration, you have a dynamic that I think Treasury will stay higher. It's not good for commercial real estate. It is higher for longer. Let's say that commercial real estate is in trouble, that the class B office space is in terrible shape, but in 18 months, things really go pear-shaped, so to speak. What impact is that on the broader economy? Because we seem to just be okay with any particular, with this issue.
8:47I mean, this report came out today. No big deal when it came to the markets. We've been saying no big deal for a very long time. Even when it comes to the regional banks, we're willing to look past it to some extent. I would have said, again, a year ago, I would have said, well, it's got to have an impact on the economy if you think about it. I mean, fewer people in office buildings. It means all the small businesses in the area are going to sort of not do particularly well. this economy is basically driven by the consumer and small business. That can't be a good recipe. But yet here we are sort of making our way through it.
9:15And it's this slow drip. I think at some point, though, that slow drip is not going to be slow anymore. It's going to start to accelerate. HYG is something I think you should look at as well in terms of credit. And Tim is right in bringing up Japan and the Bank of Japan. Not only are 10-year yields now north of 1 % in a somewhat meaningful way, their currency continues to weaken, which is somewhat counterintuitive, but actually makes sense. and you say, OK, I don't care about Japan. That's fine. But I do think it has huge ramifications for our bond market here. Let's take a step back for a minute.
9:43The rise in yields over in Japan is a push higher to yields here. Correct. I mean, that's that's how we need to think about the poor auction that we saw today for the five year note that had an impact on the tenure. That push yields higher. All these things that we don't want to necessarily pay attention to have an impact on this and therefore on rates for mortgages in general. They do. And I guess, you know, I look at Japan, who has been one of the largest buyers of treasuries, and I think they've got issues to think about. I think, you know, we've got a PCE number out on Friday. The market's looking for more signs on inflation.
10:14Inflation is kind of stuck sideways here with services side of inflation. But just, you know, back to commercial real estate. We talk about it like, could this be the next commercial mortgage back, you know, dynamic. Yeah. The size of this market makes CNBS look like a pimple. OK, you know, if you think about commercial real estate and if you think about who suffers, I mean, think about the risk that so many pension funds and endowments and municipalities have been forced to reach out to in terms of commercial real estate. You know, and we talk private credit, private credit. I mean, a lot of that also is packaged around commercial real estate.
10:47So the size of this market is is so seismic that I think it's something that you have to pay attention to, even if you have a small bit of a default ratio change. All right, let's dig deeper into this and the state of the U.S. economy and markets around the world with Rosenberg Research founder and president David Rosenberg. David, I know you've been listening into our conversation intently and with interest, and I'm wondering how you assess sort of the exposure the economy could have if this is, in fact, the next so-called shoe to drop. Right. Well, look, we saw shoes dropping last year, you know, with Silicon Valley Bank and some others.
11:20Of course, that was more being upside down on their treasury securities. And it created a ripple. But, you know, the Fed and the authorities intervened and prevented it from becoming a crisis. You know, what's interesting is that a couple of months ago, after one of the FOMC meetings at the podium, Powell, when asked, actually said that he expects that there's going to be regional bank failures this year. So he knows that this game is not over. The question is, you know, how can they smooth the transition, you know, when these regional banks start to fail? And of course, we'll see more consolidation, so on and so forth.
11:59Hey, David, it's Dan. Thanks for joining us. You've been on the lower inflation train for a very long time here. And I'm just curious where you think you see inflation in the U.S. bottoming out a little bit. And what do you think some of the ramifications might be for that? Because obviously, some of the data that we've seen of late has been a bit firmer, and inflation expectations haven't come down that much from this 3.1 % in the CPI. Well, the market-based inflation expectations have been basically stable for three years. I mean, I think the five-year and 10-year dips break evens have been stuck around 2.3%.
12:36That's nothing to be concerned about. But, you know, when you talk about U.S. inflation, I mean, firstly, it's a lagging indicator. I'm very concerned that the Fed is busy chasing lagging and contemporaneous indicators. And what's holding up the U.S. inflation rate, over and beyond the fact that we had this bump up in insurance rates, whether it was autos or whether it was home or health insurance this year, which is nothing the Fed can really control, what's holding it up for the most part is owner's equivalent rent. And, you know, what's interesting is that when you look at the U.S. inflation numbers and you put it consistently with how they do it in Europe, because Europe does not have OER, the underlying inflation rate in the United States is 1.9%.
13:17And yet nobody talks about it, I guess, except for me. Certainly the Fed doesn't. So a lot of it's going to depend, and Powell talked about this, is how painstakingly slow it's been for the rental numbers, especially OER, which is 27 % of the index, to start to soften up. But that's really, I mean, your inflation story for this year has been insurance, and it's been the rental numbers. Outside of that, there was no inflation. and the data. Hey, David, it's Courtney here, and thanks for joining. When it comes to the commercial banking space here, you saw the Fed was actually willing to come out, and they were bailing out the regional banks.
13:54And I think that somewhat did put a floor on the issue that we're seeing in the commercial space right now. And so my question to you is, how much does that going forward create a floor there? Are people not worried about what's happening in the real estate market because the Fed is willing to step in? Well, look, I mean, regional banks did fail last year. They didn't prevent that. What they prevented was a contagion. And that's what they will do again. I mean, how they end up doing it, your guess is as good as mine. Do we create a bad bank, an RTC-like situation like we have with the commercial real estate debacle of the late 1980s?
14:27The concern for, you know, the central bank is not so much about banks failing. The concern would be, does it engineer systemic risks through the financial system? And that's really what they're going to be focused on. Are you not worried because you think the Fed is going to step in? Well, I wouldn't exactly be an investor in regional banks. And I do have a more defensive bent towards the stock market. So it really depends on how you position. No, I'm not concerned this is going to turn into an unmitigated disaster. We all know the story and we know that it's going to be a suppressant on growth.
15:03You know, the conversation before about interest rates, it's not about interest rates staying stable. If we're going to actually prevent this from becoming something worse, the Fed is ultimately going to have to cut rates. They'll wait, I guess, for inflation to come down more quickly than it has. But we're not talking about just interest rates stabilizing. And when you're taking a look in the broad business sector, where these loans were originated were between 200 and 300 basis points above the level of rates right now. I mean, rates are going to have to come down a lot to stave this off alongside some of the other more direct measures that the Fed and the Treasury are going to have to make.
15:44David, it's always great to get your take. Thanks for your time. David Rosenberg, Rosenberg Research. All right. So do you think the Fed will do they have a motivation, extra motivation to get on the cutting train faster? No, no, they don't have any. They don't. In fact, they probably see their greater risk is moving too quickly to the downside, even though David's right to talk about the lag effect and essentially chasing numbers that are meaningless. If you if you think about what's going on in the past. But that's and what I heard David saying is he's more concerned about. I think I heard him saying it's more concerned about deflation rather than inflation, Because, in fact, a credit bubble, and if you think about where Japan came from after two or three decades, and even where we were coming out of the financial crisis, it's a cancer that actually erodes at growth.
16:28It's something that actually means you're fighting deflation. So there are still people that believe that that's where we are. That's the big debate. And in terms of allocators out there, a lot of people are trying to lock in higher yields now because they're not convinced yields stay higher. It's interesting. You know, we talk about the yield curve forever last year. It's forgotten. What was it? Was it a journal article, a Barron's article? Basically talking about, you know, the forgotten indicator. Nobody wants to talk about it. You should talk about it because, you know, the Fed wants to cut rates.
16:54They find they'll control the front end of the curve and maybe they'll knock 10 year, excuse me, two year yields down to four and a half percent. The problem, of course, is I think 10 year yields are going higher and that's going to be the steepening. And that's the time historically when things get dicey, when the re-steepening of the yield curve. Yeah, I mean, the other thing I would just say is that if they cut too quickly, it just might restoke inflation fears, right? And you've seen this, you know, crude oil closed above 80 for the first time in a little bit here. I do think it's interesting that the dollar has been lower, hasn't kind of rallied with yields right now.
17:25But who knows what would happen there? Obviously, if they were to cut, you would see a weaker dollar. So maybe the weaker dollar is suggesting that to us. I just don't know. I mean, at the end of the day, I think that the point you guys made about what the Fed might do, yes, they let some banks, regional banks fail last year. They're not going to let a contagion happen. I think that is the lesson over the last five years, and it goes back 15 years. All right, we've got a news alert on United Airlines right now. This follows a warning last hour from American. Let's get to Philip O. with the details.
17:55Phil. It's another 8K, Melissa, and this one from United is unlike Americans. United is reaffirming its guidance for the second quarter. We're sort of entering that period where we're going to start to get guidance in terms of how the quarter was shaping up. And despite United reaffirming its guidance, the stock is under pressure. Why? Because American Airlines has issued a warning, which has some people saying, are we going to see softness with the airline stock? So that's why it's also bringing shares of United down. Although American's warning is strictly about American, they have lowered their EPS guide.
18:28It was$1.15 to$1.45 for the second quarter. Now it's down to$1.15. with revenue now expected to fall 5 % to 6%. It was expected to fall 1 % to 3%. And the company announcing that the chief commercial officer, Vazu Raja, is leaving the company. We will hear more from Robert Isom, CEO of American Airlines, tomorrow morning at the Bernstein Conference in New York. I'm sure he'll be spelling out in greater detail exactly why it is issued this warning for the second quarter. Melissa, back to you. Phil, did I see that the guidance range for United looked like a buck wide on adjusted EPS? or 475? I have not seen that guidance yet.
19:07I have not seen that yet. And if that's the case, that probably explains some of the pressure that's there. 375. I see it here. 375 to 425 on adjusted EPS guidance. All right. Phil, thank you. Phil, a bow. So it's 50 cents wide. What do you think, Tim? I think that airlines are great trading stocks. And I think after a 70 percent move in United and Delta, which I love and I like the fundamentals of Delta, I think you've got a trend here to fight to the downside. I think if you look at United, it's traded in a range for the last almost since really since COVID. It's traded in a range from kind of 30 to 35 up to 55 to 60.
19:41And it's done that back and forth for two years. I think you I think you don't chase this one on a buy tomorrow. Coming up, some after hours action shares Akava on the move after reporting results, the details out of that quarter and how the whole fast food space is faring. That's next. And can't stop, won't stop. The Nvidia search continues with no end in sight. how our traders are handling the move ahead of the stock split when Fast Money returns.
20:10Welcome back to Fast Money. We've got an earnings alert on Kava, the company reporting a beat on the top and bottom lines, but shares stumbling on this news. Kate Rogers joins us to dig in on why. Hey, Kate. Hey, Melissa. You said it, a beat on the top and bottom lines for Kava today. EPS a really big beat, 12 cents per share. Revenue is$259 million. That includes both restaurants and consumer packaged goods at the company. Same store sales also better than expected for the quarter, up 2.3 percent. The company also raised its full year outlook for restaurant sales to a range of four and a half to six and a half percent.
20:41That's up from a range of three to five percent. It opened 14 restaurants in the quarter, bringing its total to just over 320. As for why it's down, the stock has rallied about 90 percent so far this year to date, but lower, as you mentioned, on this earnings report after that run-up. The company's CEO saying in an interview with Reuters that it has no price hikes planned for the remainder of the year and that it's really seen resiliency across income cohorts. That's something we also heard from Chipotle and Sweetgreen. Those are similar concepts and a bit more expensive names for consumers in terms of dining out in an environment where fast food itself has gotten really expensive.
21:14Melissa, back over to you. Kate, thanks. Kate Rogers down two and a half percent off a fresh record high is really not bad at all. The relief. You're right. Totally. No. And Tim, we were talking about it on the call before, and Tim can wax poetic, but it's expensive. Whatever metric you want. And I think what I think is going on here, and I think people are trying to find the next CMG, and maybe they're finding it in the form of Kava. And maybe it will wind up being that, but it's gotten itself really expensive really quickly. Good news, though, margins are really good. I mean, they beat profit margins by 210 basis points.
21:45So they're operating well. It's not an indictment of the company. I think it's an indictment of the valuation. Yeah, and I think a lot of the excitement is people are looking for another Chipotle. And I think they do have a lot of catalysts that could bring them higher. They're starting to obviously open a lot more restaurants. But a lot of those, they're starting to have drive-thrus, which have higher margins for them. They actually put a lot of money into technology, right? They're actually automating, like making pita and cutting onions. Automating and making pita. That's what I'm hearing, yes.
Read the full transcript
22:10Interesting. Which is fascinating that they can do so. But it reduced labor costs, right? So, I mean, it's actually helpful. So, I agree it's expensive. but I think longer term. I mean, it's an interesting story. It's not expensive. It's lunacy, okay? I mean, they make salads, and they're growing four and a half to five. Hold on. It's a Mediterranean bowl, Tim. Okay. I'm sorry. Look, I'm half Mediterranean somewhere in my history, and it doesn't impress me. Okay. I look at they're trading at 10 times sales. They're trading at, you saw that forward PE. I think you have a dynamic here where how can fast casual, I understand it's a different demo, but how can fast casual be doing what it's doing when fast food and essentially quick serve is actually plummeting.
22:49Look at that chart on McDonald's. Look at that chart on Wendy's. Look at that chart we heard from Restaurant International. Isn't that unfair, though? I mean, isn't that like saying how can, I don't know, a higher-end retailer be doing what Dollar General is doing? I mean, it's a completely different demographic. Yes and no. I mean, at some point there are people that are also, I would say, buying that$20 salad guy. Is that you? No. Okay. Tim, it's not a salad. It's a Mediterranean bowl. That's twice now. You would be in the market for a Mediterranean bowl with some falafel and a pita that's apparently made by a robot.
23:22They serve you the pita. I just eat the pita plain. Like, you're supposed to put hummus on it, apparently. Yeah, like all sorts of dips, baba ganoush. Excuse me? Baba ganoush. Remember, in Wedding Crashers, that's what they called. Don't just nod, Tim. I mean, help me out. I'm trying to have a serious conversation about stuff. You guys are into pita. You know, I think McDonald's is starting to get interesting. I think around 240 is where you might want to start looking in again at a multiple. Forget where the stock chart is. You're starting to be able to buy a company that I think is priced in a lot of bad news.
23:52Shaq looks expensive relative to that group unless you want to put Shaq in a different demo. That stock's in your all-time highs. You know, it's interesting. Margin improvement is kind of baked into the McDonald's story right now. To your point, though, it's down 16 % or so from those recent highs. And, you know, maybe they're offsetting these labor increases. I know you did like a little man on the street thing at McDonald's when they first viewed it. I was on the main edge of that. We were on the cutting edge of that. Well, I mean, listen, you know, this year expected to do like peak margins and improving next year.
24:22All right. Coming up, more earnings action to bring you shares of Box on the Move. After reporting results, the details out of that quarter next. Plus, NVIDIA's unbelievable rise continues as the chip giant gears up for its big 10-for-1 stock split. What to expect after that change ahead? You're watching Fast Money Live from the NASDAQ markets. I did Times Square. Back right after this.
24:48Welcome back to Fast Money Stocks. Finishing mixed to kick off the holiday shortened week. The Dow dropping more than 200 points. They have to be finishing just about flat. And the Nasdaq gaining 99 points to finish above 17 ,000 for the first time ever. NVIDIA, a key driver of those gains. The stock jumping nearly 7 % and continuing its post-earning surge. The rest of the semis riding the NVIDIA wave. Names like AMD, Micron, and Intel. Even Intel. gaining as the money keeps flowing into this AI space. So here's the question. Is NVIDIA's run lunacy, to use a word that you used earlier in relationship to Kava, or does it make sense?
25:26Because part of this is on the back of XAI, the funding round at receipt, and thinking that Elon Musk is going to buy a whole lot of NVIDIA chips for XAI. Through that lens, it makes perfect sense. Through the other lens, double, triple ordering, the fact that margins at some point are going to peak in a meaningful way, The fact that a lot of market participants think semis are no longer cyclical, which they've been the history of semiconductors. So, yeah, that's the other side of the equation. Through that one lens of everybody, the CapEx and the space, it absolutely makes sense. The other side of that mountain, though, not so much in my opinion.
25:58You believe in the other side of the mountain, though. But just so we're clear, for the last 80 percent or 100 percent. That's the thing. That's the thing. So I want to be clear about that. But that's what's fascinating about this move, because we've been talking about semis for how long? In terms of real outperformance and leading the market, two years? Okay. And so to say that semis have outperformed the market by almost 60 % in the last two years, you're not surprised to hear it. But when you hear that 45 % of that 60 % move or 75 % of the move of outperformance of semis has come since November of 23 to the present, that's crazy.
26:31Because most people in late October when the market's kind of turned, and so it's really from that moment, said, wow, boy, semis have already had an incredible run. I think we're going to see broadening in the market. We're going to see outperformance. Look, 25 percent of that move has come since April 19th of, again, the outperformance of not just NVIDIA, but semis as a group. So, yeah, Elon Musk News was part of a driver for NVIDIA today. But as we just said, the entire space was on fire. Everyone. Micron makes new highs every day. And they're not even a sexy AI play, even though they're obviously been an AI play.
27:01So can they go higher? I think they can. You know, it's interesting that NVIDIA is about to overtake Apple in market cap, right? So it's gained a half a trillion dollars in market cap just in the last three days since they reported those results. And, you know, there's a whole host of reasons why you could say, well, if I'm short, I want to cover or why people are just kind of continue to get long. You know, the stock's up a thousand percent from October 2022. And at some point, something's going to come undone here. And not only is it going to take NVIDIA down, but it's going to take the whole sector down.
27:29I go and I broaden this out a little bit and I say the hyperscalers, whether it's Microsoft, whether it's AWS at Amazon, whether it's Google Cloud, I think they're going to benefit. I think it's interesting that NVIDIA mentioned today, I think it was an information article talking about this, that their prior expectations for cloud spend went from$3.5 billion to$9 billion. Sooner or later, some of this stuff, as you see pricing come in, margins come in, and greater spend, that is going to weigh on NVIDIA shares, but it should continue to benefit the hyperscalers. You mentioned the AI adjacent, and then there's Dell, which is also reporting earnings this week.
28:01Corny, that's one that you liked. And I think that's where you do want to start to play the adjacent plays here, because I think NVIDIA can keep still going up. I think you get that FOMO trade where people, they want to get in. The higher they see it go, the more they want to get in that rally they're left out of. But it is just getting to a point that I don't think you want to chase that. So, yes, I think Dell is absolutely a beneficiary of that. You're going to see some of their hardware upgrades. You're going to need AI-enabled devices. I actually, I've said this before with the energy space.
28:26I think that's when you're going to have to power these huge data centers that comes with AI, and that's regardless of which companies are doing so. I mean, I think that's actually a really good way of playing this. Coming up, a betting bummer. Sports gambling stocks like DraftKings and Flutter sinking after one state's proposed tax hike. But is this just the beginning? Will other states follow the lead ahead? But first, a massive move in shares of Inzmet as the company's new drug blows away expectations. CEO Will Lewis is here to dig into the trial results and what it could mean for the future of the company.
28:55Back in tune. Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money Podcast. We're back right after this.
29:12Welcome back to Fast Money. Share is a biopharma company, Insmed, soaring nearly 119 % today following promising results from a phase three study of its lung treatment, Bransokatib. The study found that patients with non-cystic fibrosis bronchiectasis saw a significant reduction in symptoms. If this treatment is approved, it would be the first one to deal with this condition and might work for other hard to deal with diseases. InSmed CEO Will Lewis is here to discuss this. Will, exciting day for your company, huh? It certainly was. It's actually a fantastic day as well for the patients who have bronchiectasis.
29:45Of course. This is a condition that, as you mentioned, currently has nothing approved to treat it. And this is a landmark study, at least 50 % bigger than any other study in the field. And this has been an area where a lot of people have tried to develop drugs and have really struggled. They've all failed. So today represents a new day of hope for people with this disease. Analysts on Wall Street are very excited. Lirink, for one, compared this to potentially Dupixent, which is a$12 billion drug last year, or Humira, which at its height was a$22 billion drug in one year. And part of that enthusiasm is this mechanism of this drug, which is the DPP1 inhibitor.
30:21Can you explain, I mean, DPP-1 inhibitor does what, and what does that mean for other diseases of the lung that have been so far hard to treat? Yeah, well, it's not just diseases of the lung. It's really any, what we refer to as neutrophil-mediated disease. So this is where neutrophils are recruited to the body, different parts of the body, to address inflammatory conditions. And so by inhibiting DPP-1, you sort of break that cycle of inflammation that can lead to disease states. We talk about bronchiectasis as the first and most obvious target for this, but we also have a study underway right now in a disease called chronic rhinocytocitis without nasal polyps, and that study we'll read out next year.
31:03That, like bronchiectasis, is a disease that has nothing approved to treat it, currently numbering 26 million people in the U.S. that have that condition. So this is a very significant opportunity. We're going to focus on the most severe end of that patient spectrum, but it's still quite substantial. And DPP-1 inhibition, its day has just started today. How pivotal do you think that this mechanism will be in the long run? I mean, you're talking about a trial that's underway for CRS without polyps. And so I'm wondering, when you think about other sort of diseases that this could be applied to potentially, what does that pipeline look like?
31:38So we've actually started after our phase two results were published in the New England Journal of Medicine looking at other forms of DPP-1. So we have in our chemistry labs additional candidate compounds. So it's not just the one we brought forward today, what we refer to as brensocadib, but it's other compounds that are in development. We've looked in the preclinical disease states for things like rheumatoid arthritis, lupus nephritis, very substantial populations where there's a clear medical need. One of the diseases we're going to be looking at later this year is hydradinitis supprativa. That'll be a phase two study.
32:10It's a dermatologic condition that we'll be kicking off by the end of the year. Yeah, it's fascinating. I mean, all the inflammatory, if you think about all the biologics out there, you come right at the forefront now. You're stepping into the same class as a lot of the big cap pharma names. So my question is, you mentioned different indications. Talk about, I guess, dollars and cents. What's the potential for this drug in your estimation, to the extent you can answer that? Yeah, well, the way we like to think about it is in terms of patient impact. And so if we just take a look at bronchiectasis, at the time of launch, where we have our commercial infrastructure, which is the U.S., Europe, and Japan, there are a million patients identified today that would be suitable for treatment with this condition, assuming it received the appropriate regulatory approvals.
32:56Beyond that, I mentioned CRS without nasal polyps and the enormous size that that market opportunity represents. So these are just the beginning of several conditions that we're going to be pursuing. but each and every one of them is very substantial. You're ramping up very quickly in anticipation of regulatory approval and marketing of this drug, correct? I mean, I read that you were hiring. You put out 100 sales job postings in the past week. Yeah, that was a good sign. That's a good sign. Well, the truth is we've been preparing for this moment for a long time, and we've been working on the assumption that the data would be good.
33:29So we started with the leadership in the sales function as well as the medical function, and importantly, as we all know, the market access function. We need to be able to not only provide this drug, but make sure that the patient experience from start to finish is as smooth as it can possibly be. So yes, the latest group is 100 new job postings, but I will tell you, as somebody who's been at the company for 11 1⁄2 years, when I started, there were 30 employees. So today we number over 1 ,000, and we're well on our way to getting a lot bigger than that. Will, thanks for coming on. It's my great pleasure.
34:01Will Lewis in Smed. That was a massive stock move. And justified, by the way. And I think the Mizugou analyst, he's a physician. I can't think of his last name. I can't pronounce it. He said this will be one of the most binary outcomes we've seen in the last five years in terms of biotech. He was spot on. And the truest analyst as well. She put a$48 price target on this stock a month ago. With that said, now you're going to start to see analysts play catch up in terms of the name. So listen, huge move today. Probably just getting started. I just, you know, and what we just heard we'll talk about.
34:32I mean, there's the focus on today's data points and what they mean for, how do we pronounce that? For what? For bronchia. Bronchiectasis. But the whole, you know, rhinosinus, sinusitis. I mean, some of the. CRS. So in the entire space, there's a broader application here, thank you, for this application. And that's part of what I think the analyst community is going to jump onto. Coming up, the news that had sports betting stocks going bust. And if one state's new tax hike proposal will handicap the whole space, the details next. Fast Money is back in two.
35:07Welcome back to Fast Money Sports. Gambling stocks slipping today on news that Illinois is moving closer to a major hike on its sports betting tax. The state Senate approving the proposed bill that would switch the tax from its current 15 percent to a graduated format that could go as high as 40 percent. DraftKings and FanDuel parent flutter both down sharply today. Does this happen, Tim? Do more states follow? More states. Part of the advocacy and the follow-through for online sports betting has been because the states see and smell these tax dollars. So I do think that there's going to be more pressure.
35:44But I also think that the size of the addressable market is part of what you have to do. The market's not doing that calculation today. So what other follow-through will be is still unknown. DraftKings has had a pretty solid run, and the multiple is difficult. I own some DraftKings. I don't own Flutter. Flutter's cheaper. It may be a more interesting way to play it here. Anybody else on sports betting? Big volume today. Real quick, DraftKings traded 42 million shares, almost four and a half times normal volume. It has come off pretty significantly from that prior high we saw a couple weeks ago.
36:15I don't know. I don't think you run that far away from this. And the volume today suggests that maybe you blew some weak hands out of the name. Yeah, and I think what you need to look at with them is they are going to have this increased tax revenue. But at the same time, if they get legalized in more states, I think a lot of that likely actually will come back. So I think this will be a shorter-term issue, but ideally still a longer-term gain. All right, coming up, leasing resurgence, why the tides are turning at the dealership and how it could affect your next car decision. The details next, more Fast Money in 2.
36:53Welcome back to Fast Money Auto Leasing making a comeback. Dealers seeing more traffic, but is this sustainable? CNBC's Phil LeBeau has some answers. Hey, Phil. Hey, Melissa. This is for Sandy Cannell, the man who runs Fast Money, because it seems like I get a call from him every month or so saying, hmm, thinking about a lease on this vehicle. He's got more options now. Look at the percentage of vehicles that are sold every month because lease vehicles are measured as sold within the industry. 23.7 % of what was sold was actually leased so far this year. Big improvement over last year and 2022.
37:28So what's going on? A couple of things. There's greater supply right now as we get further and further from the chip crisis. That means the automakers are building more vehicles, sending more to dealers who have more options to lease at lower price points, by the way. And when you take a look at where North American production is, it's going to increase another 2 % this year. With that in mind, it brings up the question, will this continue? Well, as you take a look at sales, remember that there was a big drop-off in 2022, not necessarily because of demand, but because of supply. And because there was constricted supply because of the chip crisis, there were fewer vehicles that were leased.
38:05What does that mean in 2025? You've got about 1 million fewer vehicles that will be coming off lease next year. So the leasing cycle, it's been interrupted to a certain extent. It's good right now. Don't expect it to stay that way going into 2025. Finally, take a look at shares of some of the key automakers that we like to focus on. And the reason we're showing you Hyundai, Mercedes, and Volkswagen, why? Because these are among the leaders when it comes to EVs sold in the US. And I hear this from a lot of people. They're like, well, if the EVs are built elsewhere, How do we get that tax credit of$7 ,500?
38:40There's a leasing loophole, Melissa, and that allows basically all EVs to get that$7 ,500 credit when you work in a lease. That's part of what was worked into the federal tax credit. So that is a big driver of what we're seeing with EVs right now. At least for now, Phil, what does this do, or in the immediate future, what does this do for used car prices and for the value of rental car fleets? In terms of used car prices, I think that, look, it's the overall market for new that drives used car prices. And I think that they're more normalized than ever before. So you're not going to see a change there.
39:17In terms of the rental car fleets, what they're adjusting to right now in the case of Hertz, getting rid of a lot of these EVs. They've unloaded a lot of them, still have more to go. And some of the other rental car companies have a little bit of that work to do because they went so hard into saying, we're going electric. Guess what? The rental car customer was not interested in going electric. Yeah. So did you tell Sandy, the boss of Fast Money, that it's time to lease a car? I mean, that's the bottom line here, this report, right? He never makes a decision. He'll call me two weeks later, thinking about a different deal.
39:52So ironic, too, right? A man who makes a thousand decisions every day about the show cannot make a decision. Phil, thank you. Exactly. The always helpful Phil LeBeau in so many different ways. All right. What do we do with this information when it comes to a GM, a Ford, et cetera? Well, you know, kudos to Tim on this one. Toyota reported on May 8th, and they gave conservative guidance. I think they gave you an opportunity because that stock was making an all-time high. It's probably come off, I don't know, maybe 11%, 12 % since then. That's the place to be. I mean, in an environment where GM and Ford have gone nowhere for 20 years, Toyota's been lower left, upper right.
40:26That's the place to be, I think. I'm sort of surprised that Toyota didn't make it into your, it's not like Blysept. Well, it already had a big move. So it depends how one plays the acronym game. If one plays it by the rules, they make an acronym. And sometimes they reverse engineer around a word and they come up with names. I know it's not that inane, folks. We actually do smart things around this. But you could also make an argument, right, you want to buy bombed out stocks. Toyota's not bombed out. Toyota's had one of the great two-year runs any auto company's ever had. And as I listen to this greater focus on EVs, that's probably not great for Ford and GM, right?
41:00The outperformance of GM and Ford, but certainly GM over Ford since October. And it's been a massive move. It's been a 75 % move for GM. It's been built around their original ICE business with a little bit of hybrid dynamic without a focus on EV. That's why it's rallied. You know, it's interesting. Phil brought up that the rental market doesn't want EVs. And I don't know if you guys see this, if you're Uber users here, and I am in New York City. It just seems there's a ton of low-end, you know, Teslas. They've just been kind of dumped onto the Uber, whoever the Uber drivers are. I know there's organizations that kind of buy them and lease them out.
41:31So that means one thing. You know, Tesla can't get out of its own way. I'll just say this. I think it's really interesting. I know that's surprising coming out of my mouth. But you think about this. I mean, I think that that rental channel was something that they were pretty optimistic about, and that's gone away. All right. Up next, final trade.
41:51Final trade time. Tim Seymour. Altria is a name where I think for defensive staples players, this is a name giving you 9%. Courtney. We've talked about the AI adjacent trade. I think energy is how you want to play that. MLPX is the pipelines. Dan Nathan. You guys really freaked me out about all that CRE talk. Are you freaked out? I'd stay away from the KRE. Sunrise Florida tonight. What time is it? 6 o 'clock. 2 hours from now. Sunrise Florida. Sunrise Florida is a place. Sunrise Florida is a place. It's going to be a humbling experience for the Panthers. Yes, it will be, Tim Seymour. You'll be watching.
42:26Courtney will be watching. I'll be watching. Everybody. Who won't be? That's the question. What's the percentage of that? Panther fans. CDE. It's no longer Coeur d 'Alene. It's Coeur Mining. Just Coeur Mining. No Deline. All right. Thanks for watching Fast Mad Money with Jim Cramer starts right now.
42:45All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.
43:19To view the full Fast Money disclaimer, please visit cnbc.com forward slash fastmoneydisclaimer.
From the publisher
Is there more trouble brewing in the office real estate space? The shocking stat that could mean big problems for lenders, and why the government may need to get involved. Plus Insmed’s incredible day. The pharma stock surging as new drug trial results blow past expectations. What it could mean for the future of the company.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
